Zacks Investment Research
19 Jun 2026, 12:41 UTC · 1h ago
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
19 Jun 2026, 12:41 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
CareDx (CDNA) shares rose 11.5% following the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR) in the Journal of the American Society of Nephrology. — Positive clinical data for a key product (AlloSure Kidney) directly supports revenue growth and market adoption.
+0.60CareDx is expected to report quarterly earnings of $0.22 per share, a 120% year-over-year increase, on revenues of $114.35 million, up 31.9%. — Strong projected growth in both top and bottom lines typically supports a bullish valuation.
+0.50LifeMD (LFMD) consensus EPS estimates for the upcoming report have declined by 300% over the past month to -$0.2. — A significant downward revision in earnings estimates is a strong negative signal for near-term stock performance.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Shares rallied 11.5% following positive clinical study data and expectations of strong earnings growth.
Shares closed lower and the consensus EPS estimate for the upcoming report has decreased significantly.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
4h ago
